X-linked Hypophosphatemia
📧 Sign up to get email alerts when something new happens for X-linked Hypophosphatemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-04-08EMA Authorised: Crysvita (burosumab) — Kyowa Kirin Holdings B.V.
The EMA authorised Crysvita (burosumab) for X-linked hypophosphatemia and related familial hypophosphatemia and osteomalacia indications, wi…
-
FDA approval · 2020-06-18FDA Approved: CRYSVITA — Supplemental Application (Kyowa Kirin, Inc.)
The FDA approved a supplemental application for CRYSVITA (burosumab) submitted by Kyowa Kirin, Inc.
-
FDA approval · 2018-04-17FDA Approved: CRYSVITA — Original Application (Kyowa Kirin, Inc.)
FDA approved CRYSVITA (burosumab) from Kyowa Kirin as the original application for the treatment of X-linked hypophosphatemia.